Finally, recent clinical trials testing the safety and efficacy of monoclonal antibodies targeting IL-17A and IL-23 in SpA, psoriasis, psoriatic arthritis and Crohn's disease have been very encouraging and have increased the therapeutic options for these diseases. The gene discussed is IL23A; the disease is Crohn disease.